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The problem. These experiments were designed to determine 
the effects of the immunostimulant leucogenenol and the combination 
chemotherapy of arabinosyl cytosine and vinblastine on the Band T 
lymphocyte populations of mice infected with Friend virus leukemia. 
Procedure. Isolated lymphocyte populations were quanti­
tated using a cytotoxic assay for T lymphs and a direct immunofluores­
cent technique for B lymphs. Spleen and liver weight to total body 
weight ratios, survival times, peripheral nucleated cell counts and 
peripheral white blood cell differentials were also monitored to show 
the progression of the FV leukemia and the effects of leucogenenol 
and chemotherapy. 
Findings. The effect of the leucogenenol was to initially 
elevate the Band T lymphoid cell numbers of the peripheral circula­
tion significantly over the untreated controls. Increases were also 
noted between FV infected mice and those FV-infected mice that were 
given leucogenenol. The effects of the drugs were to lower the 
peripheral lymphoid cell numbers and significantly reduce the spleen 
and liver weight to total body weight ratios. Mixed effects were noted 
in all groups and at the various time intervals in the percentage of 
Band T lymphs in the spleen and lymph node cell suspensions. 
Conclusion. The effect of leucogenenol seems to be the stimula­
tion of both Band T lymphocyte stem cell lines. This is most clearly 
shown by the increase in the number of identifiable Band T lymphocytes 
in the peripheral blood. The effect of the drugs was to offset the 
effects of the FV. The addition of leucogenenol to the therapy seems 
to work in opposition to the drugs by reducing their leucopenic affects. 
Recommendations. More studies on the cellular action of leuco­
genenol are necessary. The combination of leucogenenol and an anti-B­
lymphocyte serum may prove effective in counteracting virus-induced 
leukemias. Further studies using leucogenenol on solid tumors such 
as sarcomas and carcinomas should be done as in these cases, the 
neoplasias do not directly affect the hemapoietic process. 
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INTRODUCTION AND REVIEW OF THE LITERATURE 
Surgery, radiation and chemotherapy are today the 
most widely used means of clinically treating cancers. All 
present therapeutic regimens are immunosuppressive in some 
degree to the host. Although combination drug chemotherapy 
is today widely used in cancer treatment, it has many dele­
terious effects. First, there is the toxicity of the drugs 
to the host. Many of the drugs themselves are oncogenic or 
they may effectively potentiate natural carcinogens already 
present in the host. The drugs may cripple the host's 
specific immune surveillance system (i.e., T or thymus lym­
phocyte subpopulation) and finally it can lead to a general 
weakening of the host's nonspecific defense mechanisms (Penn 
and Starzi, 1973). Researchers are now turning to various 
immunotherapeutic approaches in the hope of lessening the 
deleterious effects of the other cancer therapies by either 
lowering dosages or shortening treatment schedules. It is 
postulated that a stimulated immune system may effectively 
eliminate all tumor cells from the host, something other 
methods of therapy rarely do. It was the purpose of this 
study to examine a possible nonspecific immunotherapeutic 
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agent, leucogenenol, and to evaluate its effects on the 
host's immune system by following the changes in the Bursa 
or B and Thymus or T lymphocyte populations. 
Friend Virus 
In 1957, Charlotte Friend found in the course of exam­
ining a cell-free extract of an Ehrlich ascites tumor, an 
agent capable of producing leukemia in mice. She described 
the following physical characteristics of the agent (Friend, 
1957) . It was found to be still active after six months 
storage at -70oC or after eleven days at 4oC. It could be 
lyophilized and stored in this form for at least three 
months. Its infectivity was destroyed by heating at 560 C 
for 30 minutes or overnight exposure to ether or a 1:200 
dilution of formalin. 
Friend virus (FV), named after its discoverer, 
Dr. Charlotte Friend, is a medium sized RNA spherical virus 
that appears in two distinct forms, types A and C (Bernharo 
and Guerin, 1958). The A particle is generally found in the 
cytoplasm of infected cells, although it is occasionally 
found extracellularly (deHarven, E. and C. Friend, 1965). 
Electron microscope studies of the A particle show it to be 
doughnut-shaped with less electron density in the middle 
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than on the periphery. Its diameter averages 87 m~ and it 
mayor may not be enveloped (deHarven, E. and C. Friend, 
1958) . Studies of the C type particle shaw it to have maxi­
mum electron density in the center. The dense area is called 
the nucleoid and it contains the genome of the virus. The 
particle has a diameter of 100 mp and is encased in an 
envelope (deHarven, E. and C. Friend, 1960a). The C type 
particles are localized in cytoplasmic vacuoles, can be seen 
budding from plasma membranes and more frequently in extra­
cellular spaces. They are never truly intracytoplasmic and 
for this reason are often considered to be a mature form of 
the A particles (deHarven, E. and C. Friend, 1960b). The C 
particle envelope is acquired through a budding and trans­
formation sequence. The budding takes place both at the 
plasma membranes and in cytoplasmic vacuoles. The particles 
are seen in intimate contact with the cellular membranes of 
infected cells and budding from these membranes forms the 
C particle envelope. Acquisition of this cellular membrane 
is responsible for the ether sensitivity of the virus 
(deHarven E. and C. Friend l 1960a). FV may replicate in al 
cell without transforming it (eg. megakaryocytes), or trans­
form a cell without necessarily replicating in it (eg. 
reticulum cell) I (deHarven, E. and C. Friend 1960b).l 
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FV has been described as a leukemia of the erythroid­
myeloid series (Metcalf et al., 1959). There are several 
strains of FV that may alter the course of the disease, 
especially the blood picture (Mirand, 1965). The hemato­
logic manifestations and symptoms mentioned will be for the 
anemia-producing strain of FV used in these investigations. 
The disease is characterized by neoplastic proliferation of 
reticulum cells with associated erythroblastosis and lympho­
cytosis. A progressive leukocytosis occurs by the second 
day after infection and reaches levels of 15,OOO-30 J OOO/cu 
rom in 7-14 days. Cell counts in excess of lOO,OOO/cu rom 
can be found In the terminal phase of the disease. The 
leukocytosis lS due predominantly to an increase in lympho­
cytes. Polymorphonuclear neutrophil (PMN) levels remain 
near normal throughout the disease (Metcalf et al., 1959). 
The peripheral blood is characterized by the presence of a 
large nucleated cell called the "Friend Cell" (Friend, 1957). 
A detailed study of the pathogenesis of FV disease 
by Metcalf et al. (1959) revealed that the reticulum cells 
of the spleen seem to be the primary sites of FV infection. 
As early as three days after infection, the reticulum cells 
of the red pUlp of the spleen show signs of neoplastic 
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proliferation. These neoplastic cells enter the venous 
sinuses and are carried to the liver. At the same time, an 
accumulation of cells in the spleen causes rapid enlargement 
of the organ and in most cases, rupture in 10 to 30 days, 
resulting in death. When splenic rupture does not occur, 
hepatomegaly develops and death due to liver failure occurs 
in 50 to 80 days (Metcalf et al., 1959). Splenic enlarge­
ment is due to leukocyte and erythrocyte accumulation, neo­
plastic transformation of reticulum cells and the development 
of hemorrhagic necrosis (Elliott et al., 1970). The failure 
of the erythrocyte precursor cells to mature and the crowd­
ing out of normal erythroblastic cells in the bone marrow 
results In the anemia characteristic of the disease (Siegler 
and Rich, 1965). 
The cells that FV preferentially replicates in has 
been a source of controversy. Early work by Siegler and 
Rich (1965) and Boiron et ale (1965) suggested the site of 
FV proliferation to be proerythroblasts. This was supported 
by Patuleia and Friend (1967) who found that tissue cultures 
of undifferentiated reticulum cell sarcomas derived from 
spleen or liver cells of FV infected animals eventually 
matured into proerythroblasts. Boiron et ale (1965) suggest­
ed that the so-called "Friend Cell" is probably a proerythro­
6 
blast. Later work by Reilly and Schloss (1971) suggested 
that the erythrocytes of infected animals can be carriers of 
FV particles. FV has been seen budding from megakaryocytes 
and plasma cells (Yumoto et aI, 1965), erythroblasts, 
reticulum cells and even mature erythrocytes (Reilly and 
Schloss, 1971). Thomson (1969) postulated the myeloid series 
as the possible target cells of FV replication. This was 
based on the findings that the bone marrow, containing more 
myelocytes than lymphocytes was better able to transmit FV 
to lethally irradiated mice than was splenic tissue contain­
ing more lymphocytes than granulocytes. Bennett and Steeves 
(1970) suggest the target cells of FV replication are not 
undifferentiated stem cells but a cell between a stem cell 
and the more mature erythropoietin sensitive cell while 
Bainbridge and Bendinelli (1972) suggest the site of FV in­
fection to be a hemapoietic stem cell. 
Like all virus-induced leukemias, FV induced leukemia 
is immunodepressive in nature. One of the first immtIDosup­
pressive effects reported is a decrease in the ability of 
infected animals to respond to antigenic stimulation by 
sheep red blood cells (SRBC). The infected animals show 
reduced serum agglutinin levels and a decrease in the number 
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of plaque forming cells (PFC) , (Morton and Siegel, 1966 i 
Ceglowski and Friedman, 1969) . Koo et ale (1971 ) related 
that the depression of antibody formation was evident to 
antigens as diverse as serum proteins, bacterial extracts 
and skin allografts. The degree of suppression is related 
to the time interval between infection and stimulation. The 
greatest suppression occurred when the animals are infected 
three to eight days prior to antigenic challenge. The degree 
of suppression depended on the virus dose (Koo et al., 1971). 
Bennett and Steeves (1970) showed that FV did not impair 
graft vs host (GVH) reactions, allogenic-sensitive reactions 
or the rejection of hemapoietic allografts, but FV did impair 
the host response to SRBC. They suggested that FV selective­
ly affected precursors of humoral antibodies, the T lympho­
cyte population was not affected. However, it is now known 
that a B lymph - T lymph cooperation is necessary to produce 
a successful PFC response to SRBC (Brody, 1970). Work by 
Bendinelli (1971) showed that FV virtually abolished in mice 
the ability to produce PFC in response to SRBC. 
Bainbridge and Bendinelli (1972) showed that FV infec­
tion greatly slowed the circulation of lymphoid cells in 
infected spleens. This would in turn affect any immune 
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response that necessitates lymphocyte cooperation. This was 
substantiated by a depressed SRBC response but a normal to 
enhanced allogenic lymphoid cell response. Evidence was 
presented that FV depressed the number of B cell precursors 
of the anti-SRBC response. Cerny and Halasa (1973) studied 
the number of antigen binding rosette forming cells (T lymphs) 
present in FV infected spleens. The study showed no inhibi­
tion of rosette formation by FV but an inhibition of the 
immune response to SRBC. It was suggested that the antigen 
reactive cells may remain preserved during a virus-induced 
leukemogenesis whereas cellular differentiation leading to 
antibody formation is inhibited. Work by Friedman and 
Ceglowski (1971) and Mortenson et al. (1973) showed that FV 
causes a marked depression in cell-mediated immunity as 
revealed by delayed-type hypersensitivity reactions. In 
vitro studies show a loss of the ability of the lymphocytes 
of the spleen to migrate. There is also the loss of the 
ability of such cells to produce a migration inhibition fac­
tor (MIF) as early as three days post-infection. The degree 
of loss was related to the time after infection and the 
dosage of FV. Macrophages were shown to still be able to 
respond to MIF but lymphocytes of FV-infected animals were 
not able to produce MIF. 
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Chemotherapy 
Arabinosyl cytosine (Ara-C) is an analog of cytosine 
and was first synthesized in 1961 (Evans et al., 1961). 
Ara-C is a powerful inhibitor of DNA replication. The mode 
of action of the drug appears to be three-fold. It inhibits 
the reduction of the ribose diphosphate of cytosine to the 
corresponding deoxyribose derivative, Chu and Fischer (1962) 
and it also inhibits DNA polymerase (Kimball and Wilson, 
1968~ Graham and Whitman, 1970). Both of these events occur 
in the S-phase of the cell cycle. Ara-C also seems to have 
a limited affect on non-S-phase tumor cells. It seems to 
inhibit the incorporation of both DNA and RNA into poly­
peptides (Karon et al., 1972). 
The drug exerts its effects for only a short period 
of time. It is rapidly inactivated in vivo by deamination 
to a uracil compound. The half-life in mouse serum for a 
dose of 50 mg/kg is about 37 minutes (Mulligan and Mellett, 
1968). It is also excreted rapidly, up to 85% appears in 
the urine in a 24 hour period (Dixon and Adamson, 1965). 
The brief active period coupled with the fact that 
Ara-C has its primary affect on cells passing through the 
S-phase reduces the effectiveness of Ara-C in eliminating 
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large numbers of tumor cells. This limitation can be par­
tially overcome by the use of frequent, intermittent doses 
to act on each new segment of the cell population entering 
the vulnerable stage (Kline et al., 1966). A more effective 
solution is the synchronization of the entire cell popula­
tion so that a large number of cells are in the S-phase at 
one time (Skipper et al., 1967). Such synchronization may 
be obtained by using a metaphase inhibitor such as vinblas­
tine prior to administration of Ara-C (Valdamundi and Goldin, 
1971) . 
Ara-C used against FV leukemia in BALB/c mice greatly 
lowers the number of erythroblasts and PMN's in the periph­
eral circulation (Chirigos, 1969). A regression in spleno­
megaly and a decrease in plasma virus titers is also observed 
(Chirigos et al., 1965). Ara-C seems to have little effect 
on the number of lymphocytes and monocytes. When the drug 
1S discontinued, the depressed cell types reappear rapidly 
and overshoot normal nQmbers (Chirigos, 1969). It is not 
clear whether this is the result of direct antiviral action 
or whether it reflects a decrease in cell numbers capable 
of supporting virus multiplication. 
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Besides Ara-C cytotoxic actions against tumor cells, 
it is capable of inhibiting the replication of many viruses. 
Originally, only DNA and not RNA viruses were thought to be 
susceptible (Prince et al., 1969). However, evidence now 
shows that Moloney and Rauscher viruses, both containing RNA 
are prevented from multiplying by this drug (Hirschman et 
al., 1969). Since Rauscher virus is closely related to 
Friend virus, it is likely that Ara-C also inhibits its rep­
lication. 
Ara-C like many antitumor agents has a suppressive 
affect on the host1s immune system. Grimswold et al. (1972) 
found that Ara-C inhibits the 19 1 s and 7's hemolysin plaque-
forming cell responses. It also affected cell-mediated skin 
allograft responses. These effects depended on the dosage 
and time of administration. In mice, an early administration 
of Ara-C had no effect on skin allograft retention while a 
later dosage significantly prolonged the retention time. 
The lymphocytic cell line, for some unexplained reason, 
seems to be very susceptible to the toxic action of Ara-C 
(DiLorenzo et al., 1973). Work on Lin (1973) suggests that 
proliferating B lymphs are especially affected by the drug. 
Winkelstein (1973) found that the phytohemagglutin (PHA) 
response of T lymphs was impaired. The levels of MIF were 
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not reduced but a reduction in the number of macrophages 
was observed. He concluded that T lymphs as well as B 
lymphs were affected by Ara-C. In a study by Karchmer and 
Hirsch (1973), using Ara-C to treat zoster and herpes infec­
tions, a reduction in complement fixing antibody responses 
and interferon titers was also observed. 
Vinblastine 
Vinblastine lS an alkaloid extracted from the peri­
winkle plant (Vinca rosea Linn.) and has the empirical for­
mula C46H5809N4. It previously had the generic name vinca­
leukoblastine abbreviated VLB. The substance was found to 
have antitumor activity and a toxicity low enough to permit 
it to be of clinical value (Johnson et al., 1960). 
All aspects of the mechanisms of VLB action are not 
understood. VLB has conclusively been demonstrated to pro­
duce metaphase arrest (Cutts, 1961~ Bruchovsky et al., 1965; 
Pfeiffer and Tolmach, 1967). Bensch and Malawista (1969) 
reported that VLB causes the microtubules of the spindle 
to "crystallize" in normal mammalian cells and thus their 
use in spindle construction is prevented. 
Since the presence of cells to metaphase arrest does 
not seem to correlate with the therapeutic effects of \~B 
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(Svoboda, 1966), it 1S unlikely that this cytological affect 
is the only one the drug produces. Madoc-Jones and Mauro 
(1968) found that VLB causes death of HeLa cells during 
interphase as well as during mitosis. In other tissue cul­
ture studies, the interference with the metabolic pathways 
of amino acids leading from glutamic acid to the citric acid 
cycle and to urea is suggested (Johnson et al., 1960; 
Johnson et al., 1961). VLB may also inhibit RNA synthesis 
through its affect on the DNA-dependent RNA polymerase sys­
tem (Creasey and Markin, 1964). A study by Plagemann (1970) 
suggests variable effects of VLB depending on its concentra­
tion. At low concentrations (O.Ol-O.lmM), metaphase arrest 
was observed with no effect on cell viability and RNA. syn­
thesis. At higher concentrations (0.2-0.6mM), there was in­
hibition of the incorporation of uridine into the nucleic 
acid pool, inhibition of the conversion of ribosomal precur­
sor RNA into rRNA, dissolution of the nuclei, precipitation 
of intracellular material and subsequent cell death. Meta­
phase arrest was not observed. 
VLB produces marked hematologic effects, the most 
pronounced is a leukopenia (Johnson et al., 1963). VLB 
affects both the myeloid and lymphoid cell series (Pfeiffer 
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and Tolmach, 1967). Large lymphocyte proli£eration is in­
hibited which in turn limits an organism's ability to resist 
infection (McGregor and Logie, 1973). 
VLB's primary time of action is during the mitosis 
phase of the cell cycle when it attacks rapidly-proliferat­
ing cells preferentially. Its effectiveness as an anti-can­
cer drug is probably related to this fact. Valeriote et al. 
(1965) found VLB to be more toxic to lymphoma cells than to 
normal hemopoietic cells in AKR/J mice. Likewise, they also 
observed that colony-forming cells of the spleen were more 
sensitive to VLB than those of the bone marrow. 
Because of VLB's ability to produce metaphase arrest, 
it is a suitable agent for synchronizing a neoplastic cell 
population. When used against FV in combination with Ara-C, 
it should enhance the actions of the drug by rendering more 
cells in the S-phase of the cell cycle at one time. VLB in 
its own right should be beneficial because of its possible 
selectivity against tumor cells and its leucopenic effect. 
Leucogenenol 
Leucogenenol, a structurally complex molecule, with 
the properties of an enol and the molecular formula of 
C H NO has been isolated from Penicillium gilmanii and18 25 8 
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also human and bovine liver (Rice, 1966; Rice and Shaikh, 
1970). Leucogenenol has been found to readily form salts 
with sodium, potassium, and calcium and these salt solutions 
probably retained their biological activity for over a year, 
however an aqueous solution of leucogenenol itself readily 
loses its activity at room temperature (Rice, 1971). When 
hydrolyzed leucogenenol forms the following compounds: 
1,2 dihydroxy-3-methyl-5-oxycyclohexanecarboxylic acid, 
3-hydroxy-3-hydroxy-methyl-5-methylcyclohexane-l,2-dione, 
glycoaldehyde, amino-acetaldehyde and ammonia. This evidence 
and spectroscopic data indicates that leucogenenol is 2­
(l,2-dihydroxy-3-methyl-5-oxocyclohexyl-3,ll-dihydroxy - 11­
(hydroxymethyl)-9-methyl-l-oxa-5-azaspiro 5,5 undeca-2,4­
dien-7-one. 
Injection of as little as 1 ug/kg of leucogenenol 
elicits a leucocytosis without a febrile response (Rice, 
1968). It is not toxic in dosages as high as 500 ug/g in 
mice (Rice and Darden, 1968). Rice (1968) reported in mice 
(strain unspecified) that a large dose (200 ug/kg) of leuco­
genenol caused a decrease in neutrophils to one-half normill 
values and a corresponding greater than two-fold rise in 
lymphocytes. This was seen within four hours after injection 
16 
and persisted for twelve days. The total peripheral white 
blood cell count however remained relatively unchanged. 
Injection of leucogenenol either intravenously or intra­
peritoneally leads to an increase in the percent of neutro­
phils and later an increase in the percent of lymphocytes in 
the peripheral blood differentials of rabbits and mice (Rice 
et al., 1971a). Rice and Darden (1968) studied the effect 
of leucogenenol on bone marrow cells and found an increase 
In myeloblasts after 24 hours followed by a return to normal 
levels in five days. A slight increase in the nucleated 
erythroid cells was also observed. The basophilic, eosino­
philic and megakaryocytic series of cells did not seem to 
be affected by leucogenenol. Leucogenenol given to suble­
thally irradiated mice resulted in an increase in peripheral 
blood lymphocytes and a two-fold increase in lymphoblasts In 
the spleen at 24, 48 and 120 hours after injection (Rice 
et al., 1968). A later study on irradiated mice given leuco­
genenol and SRBC indicated a shorter latent period before 
antibody production and greater hemolysin titers than were 
found in mice not given leucogenenol. They suggested that 
leucogenenol increases the rate of transformation of pre­
cursor cells into cells capable of antibody synthesis (Rice 
eta I ., I 97 Ob) . 
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The addition of leucogenenol to tissue cultures of 
human lymphoblastic cells increases their respiratory quo­
tient and rate of cell division (Rice and McCurdy, 1972). 
Leucogenenol also affects the enzyme systems that are asso­
ciated with lymphoblastic cell transformation (Rice and 
McCurdy, 1971). 
Rice and Ciavarra (1971) and Rice et ale (1972) 
showed that leucogenenol stimulates the maturation rate of 
antibody producing cells and the subsequent elicitation of 
normal antibody titers in splenectomized rats. Autoradio­
graphic studies of the action of leucogenenol using tri­
tiated thymidine showed that the increase in PMN and the 
subsequent decrease 12 hours after injection was caused by 
an efficient sequestering mechanism in the rat. This pro­
posal was supported by increased accumulation of labeled 
neutrophils in the spleen. The lymphocytosis occurring 
after injection was accompanied by an increase in labeled 
lymphs indicating an increased maturation of lymphoid pre­
cursors (Rice et al., 1971a). Increased label was found In 
the proliferating cells of the bone marrow, transformed 
cells of the myeloid series and lymphocytes of the spleen. 
Also, an increase was found in labeled prorubricytes indicat­
ing a stimulation of the maturation of at least one type of 
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nucleated erythroid cell (Rice et al., 197Ib). The biologi­
cal activity of leucogenenol seems to be to stimulate DNA 
replication in myeloid, lymphoid and some erythroid cells 
and increase their rate of transformation. Since leuco­
genenol effects at least three cell lines, it is probable 
that its stimulatory affect is on a primitive stem cell com­
mon to all three cell lines. 
Rice et al. (1970a) and Rice and McCurdy (1973) sug­
gest that leucogenenol is probably found in all mammalian 
tissues. They cite the liver, spleen, adrenals, gonads, and 
blood as examples. Its primary biological activity is that 
of regulation of the number and types of blood cells and 
thus their associated biological activities. 
Four previous studies at Drake University have dealt 
with leucogenenol by itself and in conjunction with various 
methods of chemo- and immunotherapy in the treatment of FV 
leukemia and leukemia L1210. A study by Elliott et al. 
(1973) documents the enhancement of FV leukemia by leuco­
genenol. Significant elevations in the peripheral white 
blood cell counts were observed, also in the lymphocyte por­
tion of the peripheral blood cell differentials and spleen 
and liver weight to total body weight ratios. A decrease in 
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survival times and an increase in hemagglutination and com­
plement fixation titers to SRBC were observed when comparing 
FV + leucogenenol to FV infected animals. It was suggested 
that leucogenenol potentiated the leukemia by providing more 
sites ln which the virus could replicate and more cells that 
could be transformed by it. Also! leucogenenol evidently 
counteracted some of the immunosuppressive effects of FV by 
producing near normal antibody titers in the infected animals. 
Further studies by Averbeck (1973) and Muckerheide 
(1973) using leucogenenol and various immuno- and chemother­
apeutic procedures showed that while the drugs themselves 
were effective in prolonging the lifespan and reducing the 
parameters of the FV leukemia! the addition of leucogenenol 
did not significantly enhance the drug's action. A later 
study of Barnhill (1973)using leucogenenol and chemotherapy 
in the treatment of leukemia L12l0 showed mixed results. 
Although the lymphoid percent of the peripheral blood cell 
differentials! hematocrits and in some cases the antibody 
titers were increased, thereby showing beneficial effects, 
the survival times were not significantly increased and in 
the case of the addition of leucogenenol to chemotherapy were 
actually lowered. All studies of leucogenenol indicate that 
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it stimulates the humoral immune response in immuno-sup­
pressed animals (Rice et al., 1968, Rice and Ciavarra, 1971; 
Elliott et al., 1973; Barnhill, 1973). The effects of leuco­
genenol on leukemias leading to enhancement suggest a stimu­
lation of the cells dealing in humoral antibody production 
(B lymphs) and/or a suppression of the cell mediated immune 
response (T lymphs). 
Lymphocytes 
It is now known that the seemingly homogeneous lym­
phocyte fraction of the blood carries on at least two sepa­
rate and distinct functions. Within the last ten years, 
these lymphocytes have been separated into two distinct 
groups on the basis of physical and chemical properties, 
immune reactions and cell membrane antigens. These lympho­
cytes are basically of the thymus (T) type concerned with 
cell-mediated immune reactions or Bursa equivalent (B) type 
concerned with humoral antibody production. 
The need for quantification of the B or T ll~phocytes 
has become increasingly apparent for at least four reasons. 
First, the recognition by Hellstrom et al. (1968) and others, 
that one of the main functions of T lymphs is the inhibition 
of growth or the destruction of tumor cells. Second, the 
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realization by Hellstrom and Hellstrom (1970), Hellstrom et 
al. (1971) and Sinkovics et al. (1972) that humoral anti­
bodies may cause a phenomenon known as immunological en­
hancement of a tumor. It was found that humoral antibodies 
(called blocking antibodies) will bind to tumor cells and 
inhibit the action of T lymphs by making the tumor cells 
inaccessible to the cytotoxic action of T cells. Thirdly, 
work by Aisenberg and Block (1972) and Borella and Sen (1973) 
show that various human lympho-proliferating diseases are of 
predominately B or T lymph origin. Similar results have also 
been found in test animals. And finally, there is the real­
ization of the immunosuppressive effects of cancer chemo­
therapeutic agents and their potential inhibition of the 
host's immune surveillance mechanisms (Penn and Starzi, 1973). 
The lymphocytes dealing with cell mediated reactions 
are called T lymphocytes or thymus dependent lymphocytes. 
They have a theta (8) antigen on the cell membrane that is 
also found on >95% of all thymus lymphocytes (Raff, 1969). 
The 8 antigen has been used to develop cytotoxic assays, 
Shortman et al. (1972) and immunofluorescent assays Raff 
(1970) and Bankhurst and Warner (1971) for the quantifica­
tion of T lymphs in mice. T lymphs will also spontaneously 
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form rosettes called E-rosettes with SRBC and this has also 
been used to quantitate them (Bianco and Nussenzweig, 1971). 
Reif and Allen (1964) showed a cross-reactivity of a 8 anti­
sera with mouse brain tissue. Golub (1971) used this infor­
mation to make a rabbit anti-mouse brain-associated antisera 
(antiBA-8) that after proper absorption, proved to be speci­
fic for T lymphs. His findings were later confirmed by 
Barker et al. (1973) and Hudson and Phillips (1973). T 
lymphs are largely responsible for the recognition and the 
cytotoxic affects of the host's immune system on tumor cells 
(Hellstrom and Hellstrom, 1970). Leclerc et al. (1973) 
showed that the thymus-processed lymphoid cell subpopulation 
showing the 8 antigen is exclusively or predominantly respon­
sible for the immune cytolysis both in a syngenic tumor 
system and ln allogenic transplantation systems. 
The lymphocytes dealing with humoral antibody re­
sponses are called B lymphocytes. B lymphs possess immuno­
globulin determinants on their cell membranes, Raff et al. 
(1970), a receptor site for the third protein of complement 
(C3), Bianco and Nussenzweig (1971) and will form rosettes 
called EAC-rosettes with SRBC and an antibody to SRBC plus 
C3 (Jondal et al., 1972). Immunofluorescent techniques 
using anti-gammaglobulins have been developed for the detec­
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tion and quantitation of B lymphs (Raff, 1970~ Rabellino 
et al., 1971). 
The purpose of this study was to quantitate the 
effects of leucogenenol and chemotherapy on the Band T 
lymphocyte populations in BALB/c mice infected with FV 
leukemia. The stUdy attempts to answer the questions raised 
by previous studies at Drake University as to the specific 
immunocompetent lymphocyte populations stimulated or de­
pressed by leucogenenol injections, FV infection and the 
combination of these. 
MATERIALS AND METHODS 
Mice 
Female, BALB/c mice used throughout this study were 
obtained from the Jackson Laboratory, Bar Harbor, Maine or 
Cumberland View Farms, Clinton, Tennessee. All mice were 
from 12 to 24 weeks old. The mice were kept in disposable 
plastic cages in groups of five or six. Bedding was changed 
as needed and standard laboratory chow and water were given 
ad libitum. 
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Friend Virus 
The strain of Friend virus used in these studies was 
obtained from the Drake University stock pool. The history 
of the virus has been previously described by Elliott et ale 
(1970). The virus was kept frozen at -70oC as 20% suspension 
of homogenized BALB/c mice spleens in sucrose stabilizer. 
The virus stock was removed from -70oC storage and thawed by 
o
swirling in a 37 C water bath. The suspension was trans­
ferred to a sterile centrifuge tube and spun in a refrig­
erated centrifuge at 4 0 C for 10 minutes at 2,000 x g. One 
ml of the supernatant fluid was drawn off and a 10-3 dilution 
made using sucrose stabilizer as the diluent. All mice given 
FV received 0.3 ml volume of the 10-3 virus suspension in­
jected intraperitoneally (IP). 
Leucogenenol 
The calcium salt of leucogenenol was purchased from 
Pfanstiehl Laboratories, Inc., Waukegan, Illinois. When pur­
chased, the salt had a biological activity rating of 50%. 
The salt was dissolved in sterile pyrogen-free distilled 
water to give a 50 ug/ml concentration. A~l mice receiving 
leucogenenol were given a 0.2 ml dose (10 ug) IP at 7 day 
interval s starting 3 days before virus in fection. 
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Chemotherapy 
Vinblastine sulfate (Velban, Eli Lilly and Co., 
Indianapolis, Indiana) was obtained as a 10 mg lyophilized 
plug. The plug was dissolved in sterile, pyrogen-free dis­
tilled water. A dosage of 1.08 mg/kg in a volume of 0.1 
ml/mouse was injected IP. 
Arabinosyl cytosine hydrochloride (Cytosar, The Upjohn 
Company, Kalamazoo, Michigan) was obtained in a lyophilized 
form and was dissolved in sterile, pyrogen-free distilled 
water at pH 7.0. A dosage of 20 mg/kg in a volume of 0.1 ml/ 
mouse was injected IP. The drug sequence was given at 8 hour 
intervals on days 7 through 11 following virus infection. 
One dose of VLB was followed by 2 of Ara-C in a twenty-four 
hour period and then the sequence was repeated. Drug dos­
ages were calculated on the basis of average mouse weights. 
Rreparation and Absorption of AntiBA-8 Serum 
The antiBA-8 serum was prepared by the method of 
Golub (1971) and Barker et al. (1973). Five uninfected 
BALB/c mice were sacrificed by cervical dislocation and 
their brains aseptically removed under a laminar air flow 
hood. An equal volume of cold Hanks' Balance d Salt Solution 
(HBSS), (GIBCO), was added to the brains and then homogenized 
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ln a Virtis homogenizer. T th h . o e omogenlzed brain suspen­
sion, an equal volume of Freund's complete adjuvant (DIFCO) 
was added and an emusion made. Emulsion volumes of 0.5 to 
1.0 ml were injected subcutaneously at 2 sites on each of 
five rabbits. Each rabbit received a total of 1.5 mI. The 
procedure was repeated 7 days later. The rabbits were then 
bled by cardiac puncture on days 14 and 19. The serum, sep­
arated from the blood, was pooled and stored in 20 ml ali­
quots at -20oC. 
The antiserum was absorbed using a procedure by Barker 
et ale (1973). A homogenate of BALB/c livers and erythro­
cytes was prepared in an equal volume of HESS in a Virtis 
homogenizer. The liver-erythrocyte homogenate was washed 
5 times with HESS and 5 volumes of antisera were added to 1 
volume of the homogenate. The mixture was incubated over 
ice for one hour with occasional shaking. After centrifuga­
tion, the antiserum was further absorbed with agarose (Nutri­
tional Biochemicals Corp., Cleveland, Ohio) according to 
Cohen and Schlesinger (1970). To each ml of antiserum, 
50 mg of agarose was added and the mixture incubated over 
ice for one hour with occasional shaking. After centrifuga­
tion and discarding the agarose, the antiserum was incubated 
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o 
at 56 C for 30 minutes to l'nactl'vate 
complement and then 
stored in 1 ml aliquots at -200 C. 
Complement Preparation 
Rabbit complement (GIBCO) was obtained in a lyophi­
lized form. After reconstitution, it was absorbed with a 
liver-spleen-erythrocyte homogenate by the procedure out­
lined by Barker et ale (1973) and further absorbed with 
agarose according to Cohen and Schleisinger (1970). To cut 
down on the loss of complement due to the swelling of 
agarose, the serum was diluted 1:3 with HESS and the absorp­
tion was carried out using 80 mg of agarose per ml of com­
plement. The absorbed complement was stored in 1 ml ali-
Lymphocyte Isolation 
The isolation pDocedure and subsequent assays were 
carried out in siliconized glassware. Each mouse was sacri­
ficed by decapitation and its blood collected in aluminum 
weighing boats under a laminar air flow hood. Blood was 
immediately taken for nucleated cell counts and differentials 
before clotting occurred. The rest of the blood was added 
to an equal volume of Tris Balanced Salt Solution (Tris BSS) 
at pH 7.45 containing 10 units of heparin per mI. The 
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inguinal, brachial and axillary lymph nodes, the spleen and 
thymus were then removed and placed in vials of Tris BSS. 
These organs were ground into a fine suspension using a 
10 ml glass syringe plunger. The mouse femurs were removed 
and the bone marrow forced out and collected using a 1 ml 
tuberculin syringe filled with Tris BSS and equipped with a 
25 gauge needle. 
The cell suspensions from the blood, bone marrow, 
lymph nodes, spleen and thymus were carefully layered over 
a solution made up 24 parts of 9% Ficoll (Pharrnacia Fine 
Chemicals, Uppsala, Sweden) and 10 parts of 33% Hyapaque 
(Winthrop Laboratories, New York, N.Y.) In a 12 ml centri­
fuge tube. This solution had been made up prior to use with 
sterile pyrogen-free distilled water and had been warmed to 
0 
37 C (Fotino et al., 1971). The tubes were then spun in a 
4 0refrigerated centrifuge at C at 400 x g for 30 minutes. 
A beveled pasteur pipette was used to remove the lymphocyte 
rich layer and transfer it to 10 x 75 rom test tubes. These 
tubes were spun in a centrifuge at 2000 x g for 10 minutes. 
The excess media was removed and if erythrocytes were present, 
the cell pellet was resuspended in a tris-buffer-ammonium 
chloride solution pH 6.2-6.4 and allowed to stand one minute 
(Fotino et al., 1971). This lysed the erythrocytes and the 
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cell pellet was then washed 3 times in Tris BSS. Cell via­
bility and concentration was determined u' th tslng e rypan 
blue exclusion technique in a hemacytometer. All lymphocyte 
suspensions were finally adjusted to contain 2 x 106 viable 
cells per ml. 
Cytotoxic Assay 
The cytotoxic assay procedure was done by the method 
of Shortman et ale (1972). To 0.1 ml of each lymphocyte cell 
suspension, containing 2 x 106 cells, 0.1 ml of a suitable 
dilution of absorbed antiBA-8 was added and incubated at 
room temperature for 30 minutes. To this, 0.1 ml of 1:2 
diluted and absorbed rabbit complement was added and the 
mixture was incubated at 37 0 C for 30 minutes. Then 0.1 ml 
of 0.16% trypan blue in Tris BSS was added and the cell sus­
pension put on ice. The viability of the cell suspension 
was assayed by counting 200 cells in a hemacytometer. All 
dilutions and suspensions were added using Eppendorf Micro­
liter pipettes. Cells destroyed by the antiBA-8 and comple­
ment showed up as blue cells and were designated as T lympho­
cytes. Complement, antiserum and thymus controls were run 
with each assay to monitor specificity. Greater than 90% 
cell death in a thymus cell suspension is considered a 
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positive test of serum specifl'cl'ty. D t 
a a was recorded as % 
positive cells using the following formula (Konda et al., 
1973) . 
% positive cells = 
N positive In test - N positive in controls x 100
 
N alive in controls
 
Pluorescent Assay 
A fluorescein conjugated goat anti-mouse gamma-
globulin (Cappel Laboratories, Inc., Dawnington, Pennsylvania) 
was used for a direct fluorescent antibody technique of iden­
tifying B-lymphocytes (Rabellino et al., 1971). To the cell 
pellet obtained after 0.2 ml of each lymphocyte cell sus­
pension was centrifuged, 0.05 ml of 1:4 diluted fluorescent 
antisera was added and incubated at room temperature for 45 
minutes. After the cells were washed 3 times in Tris BSS, 
the cells were resuspended in a mounting media made up of 9 
parts glycerol and 1 part pH 7.2 phosphate buffered saline. 
One drop of the cell suspension was placed on a slide, 
covered with a coverslip and sealed with nail polish. The 
slides were examined with a Zeiss photomicroscope II under 
both ultraviolet and phase contrast. For fluorescence, the 
microscope was equipped with an Ossran HBD 200 mercury arc 
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lamp. A BG12 primary filter and a 44-50 barrier filter com­
bination was used for examining 200 cells at 600X magnifica­
tion. Lymphocytes showing fluorescence were considered B 
lymphocytes. Serum specificity was determined by thymus 
controls and trypsin treatment of the cell suspensions which 
results in a greatly decreased staining reaction. Since the 
immunoglobulin reactive sites are cell membrane bound, a 
partial reaction of the cell with trypsin removes some of 
the reactive sites and a decreased staining reaction is 
observed. 
Experimental Outline 
A total of 54 mice were analyzed as to Band T lympho­
cyte percentages. Extra mice were included in some groups 
to allow for study of survival times. The following groups 
of mice were set up and treated as indicated: 
Group I: Untreated Controls
 
Group II: Leucogenenol Controls
 
Group III: FV Controls
 
+ LeucogenenolGroup IV: FV 
Group V: FV + Leucogenenol + Ara-C + VLB 
Three mice from each group were sacrificed at weekly inter­
vals following the start of treatment. Groups were put on 
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staggered treatment schedules to allow for full attention of 
one group per day. At the time of sacrifice, blood for 
nucleated cell counts and nucleated cell differentials was 
taken. The nucleated cell counts were made with the Coulter 
Counter, Model B, in which 20 A of blood was diluted in 10 
ml of diluting fluid (Counter Counter, Inc., Hialeah, 
Florida). Differentials were stained with Wright's stain 
and 100 cells were counted and classified. Multiple counts 
were made on questionable differentials and the average of 
these counts used. Also spleen, liver and body weights were 
recorded to monitor disease progression. The group of mice 
receiving chemotherapy was analyzed at weeks 2 and 4 only. 
Results were statistically analyzed by means of a J 
standard t test. Values at the 90% (p <0.1) confidence level 
or greater were considered significant. 
RESULTS 
The values for untreated and leucogenenol control 
animals were obtained throughout the course of the four week 
experiment but will be discussed as single values. All other 
comparisons, that is FV controls. FV + Leucogenenol. and FV 
+ Leucogenenol + Ara-C + VLB groups are made on a weekly 
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basis and analyzed with a corresponding group of the same 
week. It was found in many cases that due to the small 
sample size of three animals per group that the statistical 
results gave slightly or questionable significant values 
(p <.2). It is felt in many of these cases that if larger 
sample sizes could have been used, the results would have 
been significant (p <.1) • 
The results of the peripheral nucleated cell counts 
and peripheral leucocyte differentials will not be presented 
individually. Rather, Table 1 and Figure 1 refer to average 
total peripheral lymphoid cell counts given in x 103 cells/ 
cu rom. The total peripheral lymphoid cell count/cu rom was 
obtained by multiplying each animal's total peripheral nucle­
ated cell counts in cells/cu rom by the percent of lymphoid 
cells found in its differential. To avoid confusion and con­
troversy, the term lymphoid cell will be used instead of 
lymphocyte. Thus, small, large and immature lymphocytes were 
all classified in one category. 
Upon comparing the leucogenenol control's average of 
8.07 x 103 cells/cu rom with the normal animal's average of 
3.99 x 10 3 cells/cu mm, a significant increase (p <.001) was 
Mice given FV + leucogenenol showed higher totalfound. 
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peripheral lymphoid cell counts at all four testing periods 
than the FV control anl"mals. H 1owever, on y at week two were 
the values statistically significant (p <.1), when the values 
obtained were 18.15 x 103 cells/cu mm for the FV + leuco­
3genenol group and 5.27 x 10 cells/cu mm for the FV group. 
3The FV control value of 5.27 x 10 cells/cu rom for the second 
week when compared with the FV + leucogenenol + Ara-C + VLB 
3 group value of 2.27 x 10 cells/cu mm had the same signifi­
cance (p <.1) as did the fourth week values of 59.85 x 103 
3
cells/cu mID and 24.15 x 10 cells/cu rom respectively. Com­
parisons of the total peripheral cell counts between the FV 
+ leucogenenol group and the FV + leucogenenol + Ara-C + VLB 
group for the second and fourth week were also significant 
(p <.1) with values of 18.15 x 103 cells/cu rom to 2.27 x 103 
cells/cu mm and 74.36 x 103 cells/cu rom to 24.15 x 103 cells/ 
cu mm. 
The simple percentage values for Band T lymphocyte 
assays in the peripheral blood are not presented. Instead, 
these results are multiplied by the total peripheral lym­
phoid cell counts to give the absolute number of peripheral 
3Band T lyTIphoid cell counts x 10 cells/cu ~m. The Band 
T lymphocyte results are combined in tables and charts for 
ease of interpretation. 
35 
Table 1. Average Total Peripheral Lymphoid Cell Counts 
3 
x 10 Cells/cu rom. 
Animal Group Week Total Lymphoid Cell Count 
x 103 cells/cu rom 
SD 
Group I 
Normal Controls 
1 
2 
3 
4 
3.66 
3.82 
4.48 
3.99 
1.06 
.45 
.34 
.72 
Group II 
Leucogenenol 
Controls 
1 
2 
3 
4 
7.70 
7.71 
7.36 
9.49 
.71 
.61 
.33 
3.13 
Group III 
FV Controls 
1 
2 
3 
4 
5.13 
5.27 
51.94 
59.85 
.86 
1.44 
8.28 
25.78 
IVGroup 
FV + Leucogeneno1 
1 
2 
3 
4 
5.89 
18.15 
73.96 
74.36 
.61 
9.42 
38.07 
32.50 
Group V 
FV + Leucogenenol 
+ Ara-C + VLB 
2 
4 
2.27 
24.15 
.97 
3.03 
3SD = standard deviation in 10 cells/cu rom. 
Figure 1. Total peripheral lymphoid cell 
counts x 103 eells/eu rom. All values are the average 
of 3 animals. 
Group I: Normal Controls 
[al: 
'he Group II: Leueogenenol Controls 
,he', 
at, Group III: FV Controls 
'ir 
Group IV: FV + Leueogenenol 
Group V: FV + Leueogenenol + Ara-C + VLB 
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Table 2 and Figure 2 fre er to the average absolute 
peripheral Band T lymphoid cell counts x 103 cells/cu rom 
in the peripheral blood. The B lymph population average of 
3 
3.66 x 10 cells/cu	 rom In the leucogenenol control group is 
a	 significant increase (p <.001) over the normal animal 
3 
average of 1.79 x 10 cells/cu rom. No significant difference 
was found in the B lymph population of the FV controls and 
FV + leucogenenol groups at weeks 1, 3 and 4. However, the 
3second week B lymph value of 6.47 x 10 cells/cu rom for the 
FV + leucogenenol group when compared with FV control value 
33.38 x 10 cells/cu rom was slightly significant (p <.2). 
The FV controls when compared with the FV + leucogenenol + 
Ara-C + VLB animal group at week 2 had a significant eleva­
3tion (p <.05) of B lymphs with values of 3.38 x 10 and 1.02 
3 
x 10 cells/cu rom respectively. By week 4 the values of 
347.25 x 10 and 11.51 x 103 cells/cu rom were even more sig­
nificant (p <.01).	 In comparing FV + leucogenenol group 
animals with FV + leucogenenol + Ara-C + \~B group animals, 
significant decreases in the B lymph values for the drug 
treated animals at weeks 2 and 4 were found. The B lymph 
values of 6.47 x 103 and 1.02 x 103 cells/cu rom at week 2 
had a significance of (p <.05). The fourth week values of 
e 
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3 3 
39.65 x 10 and 11.51 x 10 cells/cu rom were significant 
at the (p <.1) level. 
The T lymph values of 1.84 x 103 cells/cu rom in the 
leucogenenol controls is significant (p <.01) when compared 
to the average of .83 x 103 cells/cu rom in the untreated 
animals. No significant difference was found in the T lymph 
values of the FV controls and FV + leucogenenol results of 
the first week but the second week values of .67 x 103 cells/ 
3 
cu rom versus 2.57 x 10 cells/cu rom was significantly higher 
(p <.1). The third and fourth week values were still ele­
vated in the FV + leucogenenol group but only slightly signi­
3ficant (p <.2), 9.95 x 10 versus 19.9 x 103 cells/cu mm and 
8.94 x 103 versus 12.14 x 103 cells/cu rom respectively. At 
week two the T lymph values for the FV controls when compared 
with the FV + leucogenenol + Ara-C + VLB animal's group 
showed a decrease, but not a significant one, while the 
3 3 fourth week results of 8.94 x 10 cells/cu rom and 3.04 x 10 
cells/ell mID were slightly significant (p <.2). In comparing 
FV + leucogenenol animals with FV + leucogenenol + Ara-C + 
VLB group animals, significant results in the T lymph values 
at weeks 2 and 4 were found. The second week values of 2.57 
x 103 versus .55 x 103 cells/cu rom showed a significant 
-39 
decrease (p <.05) while the fourth week values were 12.14 
as opposed to 3.04 x 103 cells/cu « 1)
rom p • • 
Table 3 and Figure 3 refer to the percent Band T 
lymphoid cells found in spleen preparations. No significant 
change was found in the B lymph percentages when comparing 
normals and leucogenenol controls. A consistent and signi­
ficant decrease in the percent of B lymphs between the FV 
controls and FV + leucogenenol animals was found. Thus, 
second week values of 64.7% compared to 41.8% (p <.05) was 
found while third week values were 69.9% as compared to 
42.2% (p <.02) and finally for the fourth week values of 
59.6% and 46.2% (p <.02) was found. The comparison of the 
FV controls and FV + leucogenenol + Ara-C + VLB animals at 
weeks 2 and 4 for B lymphs reveals 64.7% and 54.6% as com­
pared to 59.6% and 49.7%. Both sets of values are slightly 
significant (p <.2). In comparing the FV + leucogenenol 
group with the FV + leucogenenol + Ara-C + VLB animals, an 
increase in both the Band T lymph percentages was observed, 
however, only the B lymph values of 41.8% as compared to 
54.6% at week 2 were significant (p <.01). 
A significant decrease (p <.1) in T lymphs in the 
spleen preparations was found between the leucogenenol 
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Table 2.	 Average Total Peripheral Band T Lymphoid Cell 
Counts x 103 Cells/eu mm. 
Average Total Average TotalAnimal Group Week Peripheral B 3D Peripheral	 T 3DLymph Cell Lymph Cell 
Count Count 
Group I 
Normal Controls 
1 
2 
3 
4 
1.49 
1.64 
2.25 
1. 79 
0.19 
.58 
.22 
.48 
.82 
.75 
.97 
.83 
.63 
.09 
.18 
.30 
Group II 
Leueogenenol 
Controls 
1 
2 
3 
4 
3.76 
3.35 
3.36 
4.15 
.76 
.22 
.50 
.91 
1. 53 
1.43 
1. 76 
2.64 
.20 
.84 
.75 
.69 
Group III 
FV Controls 
1 
2 
3 
4 
2.37 
3.38 
44.10 
47.25 
.23 
1.08 
6.61 
8.33 
.56 
.67 
9.95 
8.94 
.11 
.12 
3.11 
5.18 
Group IV 
LeueogenenolFV + 
1 
2 
3 
4 
2.76 
6.47 
49.56 
39.65 
.40 
2.23 
27.73 
18.14 
.78 
2.57 
19.91 
12.14 
.40 
1.00 
8.72 
5.59 
:1 
;,~. 
Group V 
FV + Leueogenenol 
+ Ara-C + VLB 
2 
4 
1.02 
11. 51 
.40 
.61 
.55 
3.04 
.39 
1.28 
SD ::::: standard deviation x 103 eells/eu rom 
Figure 2. Total peripheral Band T lymphoid 
3
cell counts x 10 cells/eli rom. All values are the 
average of 3 animals. 
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ps 
control value of 51.0% and the tun reated animal value of 
44.4%. The T lymph values for the FV controls of 32.7% 
and 25.2% for the first and second weeks when compared with 
the FV + leucogenenol values of 17.7% and 9.1% respectively 
were reduced (p <.2). It was impossible to compare weeks 3 
and 4 due to the inability to find any T lymphs in the FV + 
leucogenenol animals at that time. The second week FV con­
troIs and FV + leucogenenol + Ara-C + VLB T lymph values of 
25.2% and 11.6% were slightly significant (p <.2). 
Table 4 and Figure 4 refer to the average percent B 
and T lymphoid cells of the lymph nodes. In comparing the 
leucogenenol controls and the untreated animals, the average 
values of 47.9% and 38.7% for B lymphs proved to be slightly 
significant (p <.2). The FV controls and FV + leucogenenol 
controls showed significant decreases in the B lymph percen­
tages at week two, values of 57.1% as compared to 44.8% 
(p <.01) and week three 61. 2% as compared to 34.4% (p <.05) . 
In comparing the FV controls with the FV + leucogenenol + 
Ara-C + VLB animals, no significant change was observed in 
the B lymph percentages. The FV + leucogenenol group 
44.8% compared with the FV + leucogenenol + Ara-C + VLB group 
showed a significant increase in the second week B 
lymph values (p < .1) . 
53.8 
------------_..
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Table 3.	 Average Percent Band T Lymphoid Cells in Spleen 
Preparations. 
Animal Group 
Group I
 
Controls
Normal 
Group II
 
Leucoge nenol 
Controls 
Group III
 
FV Controls 
Group IV
 
FV + Leucoge nenol
 
Group V
 
FV + Leucoge nenol
 
+ Ara-C +	 VLB 
Week 
1
 
2
 
3
 
4
 
1
 
2
 
3
 
4
 
1
 
2
 
3
 
4
 
1
 
2
 
3
 
4
 
2
 
4
 
Average %
 
B Lymphs
 
45.9 
49.8 
50.0 
48.6 
48.8 
55.8 
46.1 
53.3 
53.9 
64.7 
69.9 
59.6 
52.2 
41.8 
42.2 
46.2 
54.6 
49.7 
SD 
3.76 
1. 57
 
2.81 
3.30 
.70
 
3.69 
7.84 
2.69 
10.82 
9.12 
8.37 
7.09 
2.62 
2.00
 
.61
 
5.49 
2.87 
6.26 
Average % 
T Lymphs 
48.1 
32.2 
52.9 
44.4 
28.9 
30.3 
30.5 
11.9 
32.7 
25.2 
4.9 
11.6 
17.7 
9.1 
0.0 
0.0 
11.6 
0.0 
SD 
4.52 
14.83 
6.73 
18.60 
3.71 
9.68 
6.54 
6.48 
5.54 
12.40 
6.95 
16.35 
12.92 
7.16 
3.41 
SD = standard deviation in % 
------------
c 
Figure 3. Percent B and T lymphoid cells in 
spleen preparations. All values are the average of 
3 animals. 
Group I: Normal Controls 
Group II: Leucogenenol Controls 
Group III: FV Controls 
Group IV: FV + Leucogenenol 
Group V: FV + Leucogenenol + Ara-C + VLB 
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The T lymph values for the normals and 
any testing 
leucogenenol 
controls showed a significant (p )<.1 reduction from 63.8% 
to 47.6%. The FV control and FV 1
+ eucogenenol values for 
the T lymph percentages were not significant at 
period. A significant decrease (p <.05) was found in the 
fourth week values of 41.7% for the FV controls as compared 
to 11.7% for the drug group. The FV + leucogenenol group 
compared with the FV + leucogenenol + Ara-C + VLB group 
showed a significant decrease in the T lymph values at week 
two, 44.9% and 30.9% (p <.02), and the fourth week values 
of 52.3% and 11.7% (p <.001). 
Table 5 refers to the average percent Band T lymphoid 
cells of the bone marrow. No consistent, significant change 
was found in making comparisons between any of the groups. 
Table 6 refers to the average ratio of the combined 
spleen and liver weights to total body weight. No signifi­
cant difference was found between the normal and leucogenenol 
controls. Although consistent increase was observed in the 
FV + leucogenenol controls when compared with FV controls, 
the increase never proved to be statistically significant. 
The FV controls when compared with the FV + leucogenenol + 
Ara-C + VLB groups showed average values of .092 and .084 
Figure 4. 
the lymph nodes. 
animals. 
Group I: 
Group II: 
Group III: 
Group IV: 
Group V: 
percent Band T lymphoid cells in 
All values are the average of 3 
Normal Controls 
Leucogenenol Controls 
FV Controls 
FV + Leucogenenol 
FV + Leucogenenol + Ara-C + VLB 
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Table 4. Average Percent Band T Lymphoid Cells in Lymph 
Nodes. 
Animal Group 
Group I
 
Controls
Normal 
Group II
 
Leucogenenol 
Controls 
Group III
 
FV Controls 
Group IV
 
FV + Leucogenenol
 
Group V
 
FV + Leucogenenol
 
+ Ara-C + VLB 
Week 
1
 
2
 
3
 
4
 
1
 
2
 
3
 
4
 
1
 
2
 
3
 
4
 
1
 
2
 
3
 
4
 
2
 
4
 
Average % 
B Lymphs 
41.9 
33.0 
41.3 
38.7 
53.3 
48.1 
46.0 
44.1 
44.7 
57.1 
61.2 
51.8 
48.5 
44.8 
34.4 
53.1 
53.8 
47.7 
SD 
8.52 
4.94 
3.85 
10.18 
5.44 
14.42 
10.52 
11.19 
6.96 
2.23 
7.53 
5.80 
3.35 
2.22
 
.70
 
7.84 
5.79 
5.70 
Average % 
T Lymphs 
74.3 
52.6 
64.4 
63.8 
52.3 
47.6 
53.0 
37.6 
26.8 
39.5 
29.8 
41.7 
19.7 
44.9 
37.4 
52.3 
30.9 
11.7 
SD 
11. 95
 
14.57 
13 .30
 
15.04 
9.69 
7.10 
5.73 
5.19 
1.80 
13.50 
6.29 
11.69 
9.96 
2.90 
7.40 
2.17 
1.48
 
.52
 
SD = standard deviation In % 
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Table 5. Average Percent Lymphoid cells in Bone Marrow. 
WeekAnimal Group 
Group I
 
Controls 1
Normal 
2
 
3
 
4
 
Group II
 
1
Leucogenenol 
2
controls 
3
 
4
 
Group III
 
1
FV Controls 
2
 
3
 
4
 
Group IV
 
1
FV + Leucogenenol 
2
 
3
 
4
 
Group V
 
2
FV + Leucogenenol 
4
+ Ara-C + VLB 
=:SD 
SD 
9.15 
8.20 
3.04 
7.35 
4.86 
3.65 
2.70 
3.37 
5.42
 
.92
 
6.44 
6.13 
2.58 
2.20 
3.30 
7.35 
2.09 
2.22 
Average %
 
B Lymphs
 
42.1 
40.9 
43.0 
42.0 
48.7 
37.9 
47.7 
45.9 
53.6 
43.1 
64.8 
42.9 
42.3 
47.8 
44.2 
46.2 
46.9 
49.0 
SD 
6.84 
3.43 
3.95 
4.99 
4.70 
3.29 
4.71 
5.29 
5.72 
6.77 
4.27 
5.96 
2.90 
3.56 
1.47 
3.23 
2.53 
7.77 
Average % 
T Lymphs 
6.8 
5.8 
4.1 
5.6 
5.2 
2.2 
6.8 
6.1 
3.8 
1.2 
5.7 
4.3 
7.0 
6.0 
5.9 
8.8 
5.5 
1.6 
standard deviation in % 
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Table 6. Average Ratio of the Combined Spleen and Liver 
Weights to Total Body Weight. 
Animal Group week Combined Liver + Spleen SD 
wt./body wt. (Average) 
Group I 
Controls 1Normal 
2 
3 
4 
Group II 
1Leucogenenol 
2Controls 
3 
4 
Group III 
1FV Controls 
2 
3 
4 
Group IV 
1FV + Leucogenenol 
2 
3 
4 
Group V 
2FV + Leucogenenol 
4+ Ara-C + VLB 
.042 
.037 
.043 
.041 
.039 
.038 
.041 
.051 
.055 
.092 
.158 
.200 
.045 
.101 
.160 
.211 
.084 
.134 
.00089 
.00032 
.00411 
.00383 
.00965 
.00259 
.00023 
.00413 
.00603 
.00595 
.01139 
.01661 
.00457 
.01723 
.02530 
.04452 
.00473 
.00521 
SD = standard deviation 
50 
respectively at week 2 (p <.2). The fourth week values of 
.200 and .134 for the same groups were significant (p <.05). 
The FV + leucogenenol animals being compared with the FV + 
leucogenenol + Ara-C + VLB animals for the second week showed 
values of .101 as compared to .084 (p <.2) and fourth week 
values of .211 as compared to .134 (p <.050). 
In comparing the FV group with the FV + leucogenenol 
group, a slight decrease in survival times and an increase in 
spleen and liver weight to body weight ratios was observed, 
however the differences in both cases were not significant. 
DISCUSSION 
The BALB/c mice T lymphocyte values of 20.4% for 
peripheral blood, 44.4% for the spleen, 63.8% for the lymph 
nodes and 5.2% for the bone marrow correspond closely to the 
values of 25%, 40%, 62% and 3% respectively found by Stobo 
and Paul in 1973. These T lymph values coupled with the 
specificity testing using a percent thymus control death of 
al so corresponds to the resultsgreater than ninety percent 
found by Golub (1971) and Kanda et al. (1973) for the use 
'c assay technique
of the complement-associated cyt a t OXl 
utilizing antiBA-G antiserum. 
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The B lymph values of 45% for th . 
c e perlpheral blood, 
48.6% for the spleen, 38.7% for the lymph nodes differ Some­
what from the 25%, 50% and 25% values for 
cell bound immuno­
globulin containing cells or B lymphs as reported by Unanue 
et al. (1973). Other reports by Rabellino et al. (1971) and 
Jones et al. (1971) give more widely varying results. 
Rabellino reported values of 45% for the spleen and bone 
marrow and 14% for the peripheral blood and lymph nodes while 
Jones reports values of 34% for the blood, 29% for the spleen 
and 18% for the lymph nodes. The discrepancies in the re­
suIts can be postula ted to have come from various sources 
including the preparation of the antisera used, the cell 
isolation and testing assays involved, the age, sex, strain, 
or health of the mice and the mechanics of the operations 
involved. Wide variations in the percentages of Band T 
lymphocytes for various mouse strains have been reported. 
Reports by Raff et al. (1970); Golub (1971); Short..man et al. 
(1972); Hudson and Phillips (1973) and Unanue et al. (1973) 
all give widely varying lymphocyte population percentages 
and could be due to any of the above reasons. 
The area of Band T lymphocyte identification and 
conflicting and contra­d manyquantitation is still new an 
Lamelin et al (1972) stated 
dictory reports can be found. 
>
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that cell-bound immunoglobulins are found 
on B lymphs and 
not on T lymphs but that not all B lymphs can be identified 
in such a manner. Stobo et ale (1973 a.) 
suggest a division 
of the T lymph population into at least two subpopulations 
based on the concentration of the €I-antigen, recirculating 
ability, radiation sensitivity, location of the cells and 
differences in cell mediated responses. Stobo et ale (1973b) 
also identified a lymphocyte population in BALB/c mice that 
has no e antigen, no cell-bound immunoglobulin and no recep­
tor for the third unit of complement. This population makes 
up an average of 10.3% of the spleen and 6.4% of the lymph 
node lymphocytes. Finally, Dickler et ale (1974) gave 
evidence for a population of lymphocytes between 1 and 6% 
that contain both a e antigen as well as a cell-bound immuno­
globulin. 
The effects of leucogenenol on the Band T lymphocyte 
populations when compared with the normal mouse lymphocyte 
populations were as follows: a significant increase in the 
number of both Band T labeled lymphocytes in the peripheral 
" . h ent of B lymphs in bothblood, a Sllght lncrease ln t e perc 
the spleen and lymph nodes and a decrease in the percent of 
Since the only real quantitativeT lymphs ~n both organs. ... 
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results were obtained from th b 
e lood, these values are 
indicative of the probable g t' 
uan 1tative changes that took 
place in the spleen and lymph nodes. These organs are the 
source of most if not all of the circulating lymphocytes in 
the adult animal. The observed slight increase in the spleen 
and liver weight to total body weight ratios could be con­
strued a s due to the gross blastic stimulat ing affect of 
leucogenenol. Work by Elliott et al. (1973) indicates a 
significant increase in peripheral nucleated cell counts of 
leucogenenol animals as compared to normals. Rice (1968) 
and Rice et al. (1968) showed a two-fold increase in lympho­
cytes and in the relative number of lymphoblast cells. The 
results here also show a two-fold increase in peripheral lym­
phocyte s. These results are suggestive of leucogenenol's 
probable role as a normal hemopoietic cell growth stimulator 
as suggested by Rice et al. (1970a) and Rice et al. (1973). 
The suggestion by Elliott et al. (1973) of leucogenenol act­
ing as a stimulator of hemopoietic stern cells and lympho­
blasts and the significant quantitative increase in the nQm­
ber of both Band T lymphs of the peripheral blood found in 
' that a preferential stimulation of B orth1S study indicate 
but rather a stimula­T lymph stem cells is probably not true 
tion of both stem cell lines is indicated. 
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The enhancing effect f 1 
o eucogenenol on FV leukemia 
can also be shown from the data. The significant increase 
in total peripheral nucleated cell counts in the second week 
indicates a more rapid progression of the leukemia. Friend 
virus's ability to replicate in progenitors of B lymphs was 
shown by Bennett and Steeves in 1970. Since the leucogenenol 
controls shewed a significant increase in blood Band T lymphs 
over normal mice, stimulation of these hemopoietic stem cells 
must have occurred. The increase in the number of lymphoid 
stem cells means an increase in the number of cells suitable 
for FV replication. Therefore, a potentiation of the disease 
as observed by Elliott et al. (1973) could occur. The in­
crease in virus replication would reduce the number of Band 
T lymphs that would reach maturation in the spleen and there­
fore a lowering of the percent of labeled Band T lymphs would 
be observed, since these lymphocytes must mature to be de­
tected by the methods used in these experiments. The increase 
in the number of peripheral B lymphs in FV infected mice 
given leucogenenol would indicate an increase in cells capa­
ble of antibody production. This was shown to be true by 
Elliott et al. (1973). This antibody production leading to 
normal humoral antibody titers in FV immunosuppressed mice 
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could produce tumor enhancement through the production of 
blocking antibodies. Sinkovics et ala (1972) reported that 
the attachment of humoral antibodies to tumor cells leads 
to inhibition of the cytotoxic effects of T lymphs, thereby 
enhancing tumor growth. 
Other immunosuppressive effects of the FV could coun­
teract the increase in T lymphs brought about by leucogenenol 
in at least two ways. Bainbridge and Bendinelli in 1972 
showed that the transit of lymphoid cells in an infected 
spleen is greatly slowed, therefore any reaction involving 
lymphocyte cooperation would be impeded. Mortenson et ala 
(1973) reported that as early as three days post-FV-infec­
tion, the ability of lymphocytes to produce MIF was lost. 
This would in turn mean that a successful T lymphocyte coop­
erative immune surveillance reaction responsible for control­
ling the emergence of a neoplasia would be reduced or elimi­
nated in the FV infected mice (Mortenson et al., 1973). 
Therefore the increase in peripheral T lymphocytes found in 
t h ese experlments. could be negated by the impeded circulation 
of lymphocytes through the spleen and the loss of the T lym­
and mount a successful immuneMIFphocyte ability to produce 
surveillance reaction. 
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The inability to find T lymphs ln the spleen of FV + 
leucOgenenol infected animals and FV + leucogenenol + Ara-C 
+ VLB animals in the final stages of the disease l'S probably 
due to the dilution of immunocompetent cell s (Dracott et al., 
1972) . Since Rice et al. (1972) showed an increase in the 
rate of transformation of immunoincompetent cells into active 
antigen reactive lymphocytes, the significant decrease ln the 
percent of B lymphs in the lymph nodes might be explained by 
a shortened time of maturation and release leading to a re­
duced buildup of mature immunoglobulin cell-bound lymphocytes 
in the lymph nodes. 
The effects of the drugs, Ara-C and VLB was to signi­
ficantly lower the total lymphoid cell counts and to signi­
ficantly decrease the identifiable Band T lymphs ln the 
peripheral blood. These decreases would tend to suggest a 
retardation of the FV leukemia through the lowering of the 
lymphoid cell numbers. The reduced B lymph percentages in 
the spleen and lymph nodes would also lend support to the 
retarding effect of the drugs through a reduction in the num­
t' Animals given FV1 ,ber of cells suitable for FV rep lca lon. 
+	 leucogenenol when compared to the drug group gave less 
of identi­
significant lymphoid cell counts and percentages 
--------'-
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fiable B or T lymphs in the peripheral blood. 
It is likely 
that the drug's cytotoxic effect on the tumor 
cells was 
counteracted by the stimulatory affects f 
o the leucogenenol. 
Ara-C has been shown by Grimswold et al. (1972) to inhibit 
hemolysin production and prolong graft retention which means 
that Ara-C effects both B and T lymphocyte responses. Lin 
in 1973 showed that combined therapy with Ara-C and VLB was 
especially effective against proliferating B lymphs. The 
results of this study seem to suggest that the drugs also 
significantly lower the percent of T lymphs in the spleen 
and lymph nodes. The effect of the leucogenenol seems to be 
to counteract some of the cytotoxic affects of the drugs. 
In the spleen this was shown by the slightly significant 
increase in percent B lymphs and no change in the T lymphs. 
Also the early increases in the percent B lymphs of the lymph 
nodes would suggest leucogenenols counteracting effects on 
the drugs. It is probable that the significant decreases in 
spleen and liver weight to total body weight ratios would 
have meant prolonged survival times which would have corre­
lated with the results of Averbeck (1973). 
'n th's area should include severalFuture work.L .L 
First of all, more mice should be sacrificed perchanges. 
--------..,..
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animal group per week. This would enable better statistical 
analysis. Secondly, an animal group .gLven FV + Ara-c + VLB 
should be included. More s t a t ements could then be made as 
to the effects of the chemotherapy and the counteracting 
effects of the leucogenenol. Further studies with leuco­
genenol might be done to monitor its effects on graft versus 
host reactions and its effect on solid tumors such as sar­
comas and carcinomas. 
SUMMARY 
The purpose of this study was to quantitate the 
effect s of leucogenenol and chemotherapy on the Band T 
lymphocyte populat ions in FV infected mice. The effects of 
leucogenenol seem to be the stimulation of both B and T 
lymphocyte stern cell lines. This was most clearly shown by 
the increase in the number of identifiable B and T lyrnpho­
cytes in the peripheral blood. The effects of the leucogene­
nol was also to increase lymphoid cell counts and to decrease 
percents of B cells in the spleen and lymph nodes. The drugs 
did offset the effects of the FV only but the addition of 
leucogenenol seems to work in opposition to the drugs by 
reducing their leucopenic effects. 
~-----_.-
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